An internal standard for the quantification of bromfenac
Related Products
Unlabeled Version(s)
23763Bromfenac (sodium salt)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Bromfenac-d4 (sodium salt)

Item No. 26598

Technical Information
Formal Name
2-amino-3-(4-bromobenzoyl-2,3,5,6-d4)-benzeneacetic acid, monosodium salt
CAS Number
2749400-35-7
Molecular Formula
C15H7BrD4NO3 • Na
Formula Weight
Purity
≥99% deuterated forms (d1-d4)
Formulation
A solid
DMSO: 100 mMEthanol: 5 mMWater: 100 mM
SMILES
BrC1=C([2H])C([2H])=C(C(C2=CC=CC(CC([O-])=O)=C2N)=O)C([2H])=C1[2H].[Na+]
InChi Code
InChI=1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1/i4D,5D,6D,7D;
InChi Key
HZFGMQJYAFHESD-OAIJHCBKSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Bromfenac-d4 is intended for use as an internal standard for the quantification of bromfenac (Item No. 23763) by GC- or LC-MS. Bromfenac is an inhibitor of cyclooxygenase 2 (COX-2; IC50 = 6.6 nM) that is selective over COX-1 (IC50 = 210 nM).1 It inhibits prostaglandin E2 (PGE2; Item No. 14010) production in a rabbit model of LPS-induced eye inflammation. Bromfenac also decreases inflammation following cataract removal in dogs when administered as a 0.9% topical solution on a tapering schedule for 24 weeks.2 Formulations containing bromfenac have been used in the treatment of postoperative inflammation following cataract surgery.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Waterbury, L.D., Silliman, D., and Jolas, T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr. Med. Res. Opin. 22(6), 1133-1140 (2006).

    2. Brookshire, H.L., English, R.V., Nadelstein, B., et alEfficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal. Vet. Ophthalmol. 18(3), 175-185 (2015).